Evaluation of the antipsychotic effect of bi-acetylated l-stepholidine (l-SPD-A), a novel dopamine and serotonin receptor dual ligand

Schizophrenia Research

Volumn 115, Issue 1, 2009, Pages 41-49

  Guo, Yang ^a   Zhang, Hai ^a   Chen, Xuetao ^a   Cai, Wenxian ^a   Cheng, Jianjun ^a   Yang, Yushe ^a   Jin, Guozhang ^a   Zhen, Xuechu ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Behavior; Bi acetylated l stepholidine (l SPD A); Dopamine D1 receptor; Phencyclidine (PCP); Schizophrenia

Indexed keywords

ARIPIPRAZOLE; BIACETYLATED LEVO STEPHOLIDINE; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; AVOIDANCE BEHAVIOR; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; HYPERACTIVITY; LOCOMOTION; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SCHIZOPHRENIA; SENSORIMOTOR NEUROPATHY; SOCIAL INTERACTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ACOUSTIC STIMULATION; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BERBERINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXPLORATORY BEHAVIOR; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); INHIBITION (PSYCHOLOGY); INTERPERSONAL RELATIONS; LOCOMOTION; MALE; PHENCYCLIDINE; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; RECOGNITION (PSYCHOLOGY); SCHIZOPHRENIA; STARTLE REACTION;

EID: 70349435270     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.08.002     Document Type: Article

References (52)

1. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int. J. Neuropsychopharmacol. 7 Suppl 1 (2004) S1-S5
2. Alex K.D., and Pehek E.A. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol. Ther. 113 2 (2007) 296-320
3. Assié M.B., Ravailhe V., Faucillon V., and Newman-Tancredi A. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J. Pharmacol. Exp. Ther. 315 1 (2005) 265-272
4. Bardin L., Auclair A., Kleven M.S., Prinssen E.P., Koek W., Newman-Tancredi A., and Depoortere R. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. Behav. Pharmacol. 18 2 (2007) 103-118
5. Barr A.M., Powell S.B., Markou A., and Geyer M.A. Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology 51 3 (2006) 457-465
6. Bruins Slot L.A., Kleven M.S., and Newman-Tancredi A. Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology 49 7 (2005) 996-1006
7. Cai N. A controlled study on the treatment of tardive dyskinesia using l-stepholidine. Chung-Hua Shen Ching Ching Shen K'o Tsa Chih 21 5 (1988) 281-283, 319
8. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., and Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 237-260
9. Castner S.A., and Goldman-Rakic P.S. Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation. J. Neurosci. 24 6 (2004) 1446-1450
10. Castner S.A., Williams G.V., and Goldman-Rakic P.S. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 287 5460 (2000) 2020-2022
11. Davis K.L., Kahn R.S., Ko G., and Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 148 11 (1991) 1474-1486
12. Ellenbroek B.A., Zhang X.X., and Jin G.Z. Effects of (-)stepholidine in animal models for schizophrenia. Acta Pharmacol. Sin. 27 9 (2006) 1111-1118
13. Freedman R. Schizophrenia. N. Engl. J. Med. 349 18 (2003) 1738-1749
14. Gao M., Liu C.L., Yang S., Zhen X.C., and Jin G.Z. l-Stepholidine increases the frequency of sEPSC via the activation of D1 dopamine signaling pathway in rat prelimbic cortical neurons. Acta. Pharmacol. Sin. 28 5 (2007) 627-633
15. 35S]GTPgammaS binding in striatum of 6-hydroxydopamine-lesioned rats. Brain Res. 841 1-2 (1999) 135-142
16. 1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl.) 174 1 (2004) 3-16
17. Grunder G., Hippius H., and Carlsson A. The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nat. Rev. Drug Discov. 8 3 (2009) 197-202
18. Gu W.H., Yang S., Shi W.X., Zhen X.C., and Jin G.Z. Effects of (-)-stepholidine on NMDA receptors: comparison with haloperidol and clozapine. Acta Pharmacol. Sin. 28 7 (2007) 953-958
19. Gurevich E.V., and Joyce J.N. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol. Psychiatry 42 7 (1997) 529-545
20. Hashimoto K., Fujita Y., Shimizu E., and Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur. J. Pharmacol. 519 1-2 (2005) 114-117
21. Hertel P., Fagerquist M.V., and Svensson T.H. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science 286 5437 (1999) 105-107
22. Huang K.X., Sun B.C., and Jin G.Z. (-)-stepholidine: a dopamine receptor antagonist shows agonistic effect on rotational behavior in 6-hydroxydopamine-lesioned rats. Acta Pharmacol. Sin. 13 1 (1992) 17-22
23. Jin G.Z. (-)-Tetrahydropalmatine and its analogues as new dopamine receptor antagonists. Trends Pharmacol. Sci. 8 (1987) 81-82
24. Jin G.Z., Huang K.X., and Sun B.C. Dual actions of (-)-stepholidine on dopamine receptor subtypes after substantia nigra lesion. Neurochem. Int. 20 (1992) 175S-178S (Suppl.)
25. 2 receptor antagonist actions. Trends Pharmacol. Sci. 23 1 (2002) 4-7
26. 1A receptor. Eur. J. Pharmacol. 441 3 (2002) 137-140
27. Kapur S., and Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry 153 4 (1996) 466-476
28. Knable M.B., and Weinberger D.R. Dopamine, the prefrontal cortex and schizophrenia. J. Psychopharmacol. 11 2 (1997) 123-131
29. Laviolette S.R. Dopamine modulation of emotional processing in cortical and subcortical neural circuits: evidence for a final common pathway in schizophrenia?. Schizophr. Bull. 33 4 (2007) 971-981
30. Le W. Clinical study on the treatment of dyskinesia by l-stepholidine. Chung-Hua Shen Ching Ching Shen K'o Tsa Chih 22 6 (1989) 335-337 381-382
31. Lee P.R., Brady D.L., Shapiro R.A., Dorsa D.M., and Koenig J.I. Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin. Neuropsychopharmacology 30 10 (2005) 1883-1894
32. 1 receptor binding associated with cognitive training. Science 323 5915 (2009) 800-802
33. Mo J., Guo Y., Yang Y.S., Shen J.S., Jin G.Z., and Zhen X. Recent developments in studies of l-stepholidine and its analogs: chemistry, pharmacology and clinical implications. Curr. Med. Chem. 14 28 (2007) 2996-3002
34. Mo J., Zhang H., Yu L.P., Sun P.H., Jin G.Z., and Zhen X. l-Stepholidine reduced l-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease. Neurobiol. Aging. (2008) 10.1016/j.neurobiolaging.2008.06.017
35. Nagai T., Murai R., Matsui K., Kamei H., Noda Y., Furukawa H., and Nabeshima T. Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D(1) and serotonin 5-HT (1A) receptors. Psychopharmacology (Berl.) 202 1-3 (2009) 315-328
36. Natesan S., Reckless G.E., Barlow K.B., Odontiadis J., Nobrega J.N., Baker G.B., George S.R., Mamo D., and Kapur S. The antipsychotic potential of l-stepholidine-a naturally occurring dopamine receptor D1 agonist and D2 antagonist. Psychopharmacology (Berl.) 199 2 (2008) 275-289
37. Odontiadis J., Mackenzie E.M., Natesan S., Mamo D., Kapur S., and Baker G.B. Quantification of l-stepholidine in rat brain and plasma by high performance liquid chromatography combined with fluorescence detection. J. Chromatogr., B. Analyt. Technol. Biomed. Life Sci. 850 1-2 (2007) 544-547
38. Ogren S.O., Eriksson T.M., Elvander-Tottie E., D'addario C., Ekstrom J.C., Svenningsson P., Meister B., Kehr J., and Stiedl O. The role of 5-HT(1A) receptors in learning and memory. Behav. Brain Res. 195 1 (2008) 54-77
39. Okubo Y., Suhara T., Suzuki K., Kobayashi K., Inoue O., Terasaki O., Someya Y., Sassa T., Sudo Y., Matsushima E., Iyo M., Tateno Y., and Toru M. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385 6617 (1997) 634-636
40. Olsen C.K., Kreilgaard M., and Didriksen M. Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats. Pharmacol. Biochem. Behav. 84 2 (2006) 259-265
41. 1-like receptor agonists. Neurochem. Res. 25 6 (2000) 759-767
42. Sams-Dodd F. Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats. Behav. Pharmacol. 6 1 (1995) 55-65
43. Shi W.X., Chen Y., and Jin G.Z. Effect of l-stepholidine on rotational behavior in rats. Acta Pharmacol. Sin. 5 4 (1984) 222-225
44. Stahl S.M., and Shayegan D.K. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J. Clin. Psychiatry 64 Suppl 19 (2003) 6-12
45. Sumiyoshi T., Stockmeier C.A., Overholser J.C., Dilley G.E., and Meltzer H.Y. Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res. 708 1-2 (1996) 209-214
46. Sun P.H., Wang J.R., Gu W.H., Cheng W., Jin G.Z., Friedman E., Zheng J., and Zhen X. PSD-95 regulates D(1) dopamine receptor resensitization, but not receptor-mediated Gs-protein activation. Cell Res. (2009) 10.1038/cr.2009.30
47. Takahashi H., Kato M., Takano H., Arakawa R., Okumura M., Otsuka T., Kodaka F., Hayashi M., Okubo Y., Ito H., and Suhara T. Differential contributions of prefrontal and hippocampal dopamine D(1) and D(2) receptors in human cognitive functions. J. Neurosci. 28 46 (2008) 12032-12038
48. Tang Y.P., Shimizu E., Dube G.R., Rampon C., Kerchner G.A., Zhuo M., Liu G., and Tsien J.Z. Genetic enhancement of learning and memory in mice. Nature 401 6748 (1999) 63-69
49. Wadenberg M.L., and Hicks P.B. The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?. Neurosci. Biobehav. Rev. 23 6 (1999) 851-862
50. Weiner D.M., Burstein E.S., Nash N., Croston G.E., Currier E.A., Vanover K.E., Harvey S.C., Donohue E., Hansen H.C., Andersson C.M., Spalding T.A., Gibson D.F., Krebs-Thomson K., Powell S.B., Geyer M.A., Hacksell U., and Brann M.R. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J. Pharmacol. Exp. Ther. 299 1 (2001) 268-276
51. Yang C.R., and Chen L. Targeting prefrontal cortical dopamine D1 and N-methyl-d-aspartate receptor interactions in schizophrenia treatment. Neuroscientist 11 5 (2005) 452-470
52. Zhang Z.J., Jiang X.L., Zhang S.E., Hough C.J., Li H., Chen J.G., and Zhen X.C. The paradoxical effects of SKF83959, a novel dopamine D1-like receptor agonist, in the rat acoustic startle reflex paradigm. Neurosci. Lett. 382 1-2 (2005) 134-138